Simpler, Faster, Cheaper Advanced Therapy Manufacturing With Intensified Lentiviral Vector Production

The rising tide of innovative cell therapies, particularly CAR-T cell therapies, has created a surge in demand for lentiviral vectors, the critical tools for engineering therapeutic cells. Current lentivirus production methods, however, struggle to keep pace, hindering the widespread availability of these life-saving treatments.

This bottleneck necessitates a revolution in lentivirus manufacturing, demanding higher yields and more efficient processes. A groundbreaking study introduces a novel approach using TFDF® perfusion technology to intensify cell culture, achieving a remarkable tenfold increase in active lentivirus production compared to traditional batch methods. This dramatic improvement unlocks the potential for significantly reduced costs, smaller bioreactor footprints, and streamlined production timelines. Imagine producing enough lentivirus for a Phase II/III clinical trial with just a 10L bioreactor, a feat previously requiring a 200L vessel. This advancement promises to accelerate the commercialization of CAR-T and other advanced therapies, bringing them to patients faster.

Learn more about this game-changing technology and its impact on the future of cell therapy by accessing the application note below.